Ensuring equitable access to essential medicines while upholding intellectual property rights (IPRs) under WTO agreements, particularly TRIPS.

Evaluating the impact of patents and pharmaceutical monopolies on drug affordability and innovation.

Addressing waivers and flexibilities in IPR frameworks during global health crises, such as pandemics.

Promoting public-private partnerships to enhance research, development, and distribution of life-saving medicines.

Strengthening international cooperation to balance economic incentives for pharmaceutical companies with the humanitarian need for affordable healthcare.